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Anthrax: A motor protein determines anthrax susceptibility
Philip C. Hanna
A new study has found that polymorphisms in the host
gene kif1C, which encodes a kinesin-like motor protein,
determine whether mouse macrophages are resistant or
sensitive to anthrax lethal toxin. These findings may
lead the way to discovering how both germ and host
factors might contribute to a lethal infection.
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Infectious disease researchers, among their other duties,
are charged with learning the molecular mechanisms that
microbes use to cause disease. To their credit, much — but
by no stretch most — has been uncovered about how many
pathogens go about their business, and about the factors
that influence, sometimes even control, the establishment,
spread and outcome of infections. Models, many quite
compelling, are presented weekly that describe specific
roles for virulence genes, products and systems. There is
no doubt that great progress in molecular pathogenesis has
been made in the past few decades. Even our understand-
ing of how differences in host physiology influence the
course of an infection is growing by leaps and bounds.
These host differences, some of them quite subtle, fall
between species, groups and even individuals, and can
clearly govern whether one exposed person may become
mildly ill, another gravely ill and a third not ill at all.
Deconvoluting the innumerable complexities of both the
microbe and the host, and all the potential vying interac-
tions between their molecules, currently confounds even
our most advanced models. More data are ever required!
Still, with the advent of modern methods for genomic,
proteomic and global genetic analysis, delineation of all
molecular interactions occurring between host and pathogen
is perhaps approachable. But distilling out of the immense
profusion of old and new information the key molecules
and interactions that might aid in countering the infection
remains a cardinal challenge.
Bill Dietrich and colleagues at Harvard Medical School
have taken a close look at a key host–pathogen interaction
occurring during the notorious disease anthrax, caused by
the bacterial pathogen Bacillus anthracis. Their research,
published recently in Current Biology [1], focuses on the
pivotal interactions between one of the pathogen’s central
virulence factors, anthrax lethal toxin (LeTx), and one of
the host’s central defensive cells, the macrophage. They
have identified a gene that determines whether mouse
macrophages are resistant or sensitive to LeTx, and which
turns out to encode a kinesin-like motor protein.
Systemic anthrax is an overwhelming and often fatal
bacterial infection that is a frank veterinary disease and
quite rare in humans (see [2–5] for reviews). Systemic
anthrax in humans is initiated when dormant B. anthracis
spores enter the body via inhalation, ingestion of meat
from animals that have died of the disease, or spread from
a localized lesion associated with the milder cutaneous
form of the disease [2]. During inhalation anthrax, endo-
spores are taken up by phagocyte cells in the lungs and are
carried to the draining mediastinal and peribronchial
lymph nodes. Inhalation anthrax is not a true pneumonia:
the lungs act as the portals to the body. Spores break dor-
mancy, escape into the blood and multiply there to high
numbers, sometimes exceeding 108 vegetative Gram-posi-
tive bacilli per millilitre of blood. Initial symptoms are
vague, ‘flu like’ and usually occur 5–10 days after expo-
sure, but they can sometimes occur either earlier or up to
six weeks after exposure, probably reflecting differences
in absolute numbers of endopsores inhaled or the time it
takes spores to be scavenged by alveolar macrophages. A
few days after onset of initial symptoms, the disease takes
its fulminant course, usually resulting in death if treatment
was not begun before the symptoms appear. Extrapolated
from studies with non-human primates, it is estimated that
an ID50 for humans is in the range of 8,000–50,000 spores.
At the center of lethal anthrax pathologies lies the toxin
LeTx, made up of two proteins, encoded on virulence
plasmid pXO1, which act in concert. The protective antigen
(PA) binds to host cells and ‘injects’ the catalytic protein,
lethal factor (LF), into the cytoplasm [2,5]. In the cyto-
plasm, LF acts as a zinc-metalloprotease that has been
shown to cleave MAP kinase kinase [6]. LeTx is inti-
mately involved with the course of infection [5]: PA- or
LF-minus anthrax strains are attenuated; animals chal-
lenged with purified LeTx present symptoms closely
mimicking those of an anthrax infection (including death);
and passive or active immunity to PA protect against spore
challenge (hence the name ‘protective antigen’). The
macrophage itself appears to be the central arena of LeTx
activities. Although LeTx can enter most cells types,
macrophages are uniquely susceptible, lysing in about
2 hours in culture [7]. They may also play a larger role
in LeTx toxicity, as mice without a full complement
of macrophages are resistant to lethal doses of the toxin
[8]. These professional phagocytes, prevalent throughout
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the body, are a key component in innate immunity. They
also are capable of initiating hyperinflammatory cascades
involved with many forms of septic and toxic shock [2,8].
In a series of elegant experiments, Dietrich’s group [1] has
exploited the innate differences in sensitivities to LeTx
between inbred strains of mice to discover a single gene
that determines macrophage sensitivity to the cytotoxic
action of LeTx. In earlier work [9,10], the group found
that macrophages from various inbred mouse strains fall
into two groups: those readily killed by LeTx, and those
that are toxin-resistant. This paralleled the patterns
reported in the toxin-sensitivities of the animals them-
selves. By cross-breeding and genetic analyses, the group
determined that the sensitive versus resistant phenotype is
controlled by a region on chromosome 11, which they
named the ltxs1 (lethal toxin sensitivity) locus. 
In their new work [1], the Dietrich group used positional
cloning to show that polymorphisms in a single gene in
the ltxs1 region, kif1C, is responsible for the sensitivity
groupings. The product of this gene, Kif1C, turns out to
be a kinesin-like motor protein of the UNC104 subgroup,
involved in cellular transport systems. The results show
that the two susceptibility groups appear identical in the
early steps of intoxication, which include binding to
membrane surface receptors, toxin processing and activa-
tion, and uptake into endosomes and delivery of the LF
moiety into the cytoplasm. From the data, the authors con-
clude that, despite the likely role of Kif1C in intracellular
transport, the kif1C polymorphisms do not appear to affect
early LeTx events but rather those occurring after entry,
though Kif1C’s exact role remains to be determined.
There are also two interesting surprises arising from this
study. The first is that it is macrophages carrying the wild-
type kif1C gene that are resistant to LeTx killing, and it is
the mutated versions of this gene that give rise to the sen-
sitive phenotype. This is surprising as most species and
their macrophages are not considered resistant to the effects
of LeTx, though mice may be a bit more so than other
species. One might have predicted, beforehand, that wild-
type Kif1C might correlate with the prominent sensitive
phenotype observed. The second surprise is that MAP
kinase kinase, a cytoplasmic substrate of LF enzymatic
activity, is equivalently cleaved in both sensitivity groups.
This finding now places the effects of the kif1C polymor-
phism downstream of the toxin’s catalytic activities, and
perhaps questions whether MAP kinase kinase inactiva-
tion by LF is involved directly in the toxic cascade.
Although we are far from having a complete understanding
of all the steps in anthrax LeTx actions, these new studies
enhance our understanding of anthrax and identify a single
host gene that predicates mouse sensitivity or resistance to
this important virulence factor. Any role that Kif1C might
play in human anthrax needs to investigated further, and
the role of LeTx in anthrax remains an important area of
future research. It has been suggested that therapies that
neutralize the LeTx might be useful in supplementing
conventional antibiotics in the instance of human anthrax.
Two approaches now being considered in this area are
passive administration of neutralizing antibodies and use
of a dominant-negative form of the PA protein that blocks
the entry of LF into cells [11,12]. With the atomic struc-
ture of PA solved [13] and the structure of LF expected to
be available soon, it also may be possible to design small
molecules that interfere with LeTx action. Whether any
toxin-centered therapeutic might be useful within the
tight timetable presented in cases of systemic anthrax will
depend upon both pharmacological effectiveness and
whether the drug can be administered before the toxin can
perform its deadly functions. The window of opportunity
might turn out to be before, or immediately after, onset of
symptoms. This is much the same scenario as we
encounter currently with the microbe and conventional
antibiotics such as penicillin and Ciprofloxacin.
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